冠昊生物(300238) - 2021 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2021 was CNY 109,590,960.17, a decrease of 5.07% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2021 reached CNY 19,554,289.44, an increase of 97.64% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 12,071,544.99, up 63.28% from the previous year[5]. - Basic earnings per share for Q3 2021 was CNY 0.07, representing a 75.00% increase year-on-year[5]. - The net profit for Q3 2021 was CNY 48,089,015.65, an increase of 33.1% compared to CNY 36,138,285.57 in Q3 2020[21]. - The total comprehensive income for the period was CNY 46,801,724.79, compared to CNY 34,199,648.53 in the prior year, marking an increase of 36.9%[22]. - The company achieved a total profit of CNY 67,204,965.76, compared to CNY 49,336,996.86 in Q3 2020, reflecting a growth of 36.2%[21]. Cash Flow and Operating Activities - Cash flow from operating activities for the year-to-date period was CNY 91,393,514.30, an increase of 39.03%[5]. - The cash flow from operating activities generated a net amount of CNY 91,393,514.30, compared to CNY 65,734,489.80 in the previous year, indicating a year-over-year increase of 38.9%[24]. - The company reported a total revenue from operating activities of CNY 66,667,108.58, up from CNY 49,177,931.79 in the same period last year, reflecting a growth of 35.7%[21]. Assets and Liabilities - Total assets at the end of Q3 2021 were CNY 1,136,804,048.31, a slight increase of 0.18% from the end of the previous year[5]. - As of September 30, 2021, total assets were RMB 1,136,804,048.31, slightly up from RMB 1,134,727,829.20 at the end of 2020[19]. - Current assets totaled RMB 448,480,862.59, an increase from RMB 438,034,052.02 at the end of 2020[17]. - Total liabilities decreased to RMB 372,844,609.04 from RMB 418,068,165.87 at the end of 2020, indicating a decline of 10.8%[18]. - Current liabilities reached CNY 302.70 million, with short-term borrowings at CNY 102.88 million and accounts payable at CNY 3.01 million[28]. - Non-current liabilities totaled CNY 115.37 million, including long-term borrowings of CNY 54.60 million and deferred income of CNY 49.45 million[29]. - The total liabilities and equity combined were CNY 1,134.73 million, consistent with total assets[29]. Research and Development - R&D expenses for the year-to-date period were CNY 33,891,458.43, a 40.73% increase compared to the same period last year, indicating increased investment in innovation[10]. - Research and development expenses increased to RMB 33,891,458.43, representing a rise of 40.5% compared to RMB 24,082,618.24 in the previous year[19]. Shareholders' Equity - The company’s total equity attributable to shareholders increased by 7.97% to CNY 788,456,314.40 compared to the end of the previous year[5]. - Shareholders' equity stood at CNY 716.66 million, with a capital reserve of CNY 599.02 million[29]. Tax and Expenses - The company reported a significant increase in tax expenses, totaling CNY 19,115,950.11, up 44.83% due to higher overall profits[11]. - The total operating expenses were CNY 329,023,162.31, slightly up from CNY 323,243,810.13 in the same period last year[24]. - Total operating costs amounted to RMB 322,307,582.50, up 16.3% from RMB 276,953,664.43 year-on-year[19]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[21].